Conecte-se

Bibliografias temáticas / Cell-based immunotherapy / Livros

Siga este link para ver outros tipos de publicações sobre o tema: Cell-based immunotherapy.

Livros sobre o tema "Cell-based immunotherapy"

Autor: Grafiati

Publicado: 7 de dezembro de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 15 melhores livros para estudos sobre o assunto "Cell-based immunotherapy".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

García-Olmo, Damián. Cell therapy. Editado por García-Verdugo José Manuel. New York: McGraw-Hill Interamerica, 2008.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Kang, Chʻang-yul. Pairŏsŭ pektʻŏ ro hyŏngjil toiptoen hangwŏn chesi sepʻo ŭi myŏnyŏk chʻiryoje yuhyosŏng pʻyŏngka mit sihŏmpŏp yŏnʼgu =: Development and estimation of immunotherapeutic cell-based vaccine approaches using antigen presenting cells transduced with viral vector. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Cell-Based Cancer Immunotherapy. Elsevier Science & Technology Books, 2024.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Borrego, Francisco, Susana Larrucea, Rafael Solana e Raquel Tarazona, eds. NK Cell-Based Cancer Immunotherapy. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-934-1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Santich, Brian H., Nai-Kong Cheung e Christian Klein, eds. Bispecific Antibodies for T-Cell Based Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-415-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Dal Col, Jessica, Alejandro López-Soto e Riccardo Dolcetti, eds. Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-726-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Ascierto, Paolo A., David F. Stroncek e Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2019.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Ascierto, Paolo A., David F. Stroncek e Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Ascierto, Paolo A., David F. Stroncek e Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology Books, 2024.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology, 2024.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Cifaldi, Loredana, Daniel Olive e James Di Santo, eds. Molecular Strategies Aimed to Boost NK Cell-based Immunotherapy of Cancer. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-876-5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Texto completo da fonte

Resumo:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Alharbi, Yousef, Manish S. Patankar e Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Texto completo da fonte

Resumo:

With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secreted factors that promote tumor growth: targets in this class include vascular endothelial growth factor, cytokines, and chemokines. The development of each of these is described. The chapter also discusses the complications presented by soluble antigens, which serve to limit the applicability of antigens (such as MUC16/CA125) that are both cell-surface associated and circulating and the prospects for the combination of antibody-based immunotherapy and chemotherapy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Abe, Hiroyuki, Amane Sasada, Shigeki Tabata e Minako Abe. Heat Shock Protein Vaccine Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0009.

Texto completo da fonte

Resumo:

Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis. Therefore important effective treatments are urgently needed. Many studies have reported that the immune system plays a critical role in disease progression and overall survival. One known effective immunotherapy is the dendritic cell (DC)-based vaccine pulsed with tumor-associated antigens. This chapter reports on a method of production of a novel DC-based vaccine. The key technologies are (a) monocyte collection without leukapheresis, (b) monocyte expansion, (c) production of dendritic cells, (d) multiple overlapping long peptides with heat shock protein 70, and (e) combination immunotherapy approach. The next generation of immunotherapy for ovarian cancer will be focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. Possible combinations which might be useful to help patients with ovarian cancer are summarized in this chapter.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!